POLISCOPE
Back to feed
NewsPBS NewsHourMay 5, 2026United States

White House Projects $529 Billion in Savings from New Drug Pricing Deals

The White House estimates that new agreements with pharmaceutical companies to align U.S. drug prices with international rates could save $529 billion over the next decade. While the administration touts these deals as a major step in lowering costs, Democratic lawmakers and outside economists have raised questions regarding the transparency of the agreements and the actual impact on patient out-of-pocket expenses.

prescription drugshealthcare policyeconomymedicaidpharmaceutical industryfederal budget
Read the full story at PBS NewsHour

Why It Matters

The policy aims to lower prescription drug costs for U.S. consumers and save federal and state governments $64.3 billion in Medicaid spending over the next 10 years, though the specific terms of the deals remain undisclosed.

Key Facts

  • The White House estimates $529 billion in total savings over the next decade from new drug-pricing deals.
  • Federal and state governments are projected to save $64.3 billion on Medicaid over the next 10 years.
  • One internal model suggests potential savings could reach as high as $733 billion over a decade.
  • 17 leading pharmaceutical companies have entered into these pricing agreements.
  • The administration has not released the full text of the agreements, citing sensitive financial data and trade secrets.
  • Americans spent $467 billion on prescription drugs in 2024.
  • A report from Sen. Bernie Sanders' staff found that 15 of the participating companies saw combined profits jump 66% to $177 billion over the past year.
  • The Congressional Budget Office previously estimated a similar plan could reduce drug prices by more than 5%.
  • Senate Democrats have proposed a measure requiring the administration to disclose the terms of the agreements.

Who's Mentioned

personRon Wyden“Senate Finance Committee Ranking Member”organizationCongressional Budget Office“Provided independent analysis of similar pricing plans”personBernie Sanders“U.S. Senator”personRobert F. Kennedy Jr.“Health Secretary”organizationDepartment of Health and Human Services“Promoting the drug-pricing deals”personDonald Trump“President of the United States”organizationWhite House Council of Economic Advisers“Conducted the savings analysis”